$19.25
0.16% today
Nasdaq, Jul 17, 03:49 pm CET
ISIN
US7665596034
Symbol
RIGL
Sector
Industry

Rigel Pharmaceuticals, Inc. Stock price

$19.28
-1.15 5.63% 1M
+1.93 11.12% 6M
+2.46 14.63% YTD
+8.03 71.38% 1Y
+6.98 56.75% 3Y
-13.52 41.22% 5Y
-12.32 38.99% 10Y
-188.92 90.74% 20Y
Nasdaq, Closing price Wed, Jul 16 2025
+0.38 2.01%
ISIN
US7665596034
Symbol
RIGL
Sector
Industry

Key metrics

Basic
Market capitalization
$344.6m
Enterprise Value
$327.2m
Net debt
positive
Cash
$77.1m
Shares outstanding
17.9m
Valuation (TTM | estimate)
P/E
9.5 | 16.3
P/S
1.7 | 1.7
EV/Sales
1.6 | 1.6
EV/FCF
9.2
P/B
18.6
Financial Health
Equity Ratio
2.0%
Return on Equity
531.8%
ROCE
40.2%
ROIC
65.3%
Debt/Equity
3.2
Financials (TTM | estimate)
Revenue
$203.1m | $205.1m
EBITDA
$46.4m | $28.8m
EBIT
$43.9m | $29.4m
Net Income
$37.2m | $21.1m
Free Cash Flow
$35.6m
Growth (TTM | estimate)
Revenue
68.7% | 14.4%
EBITDA
444.4% | 9.1%
EBIT
398.0% | 21.4%
Net Income
287.8% | 20.5%
Free Cash Flow
621.9%
Margin (TTM | estimate)
Gross
89.6%
EBITDA
22.8% | 14.1%
EBIT
21.6%
Net
18.3% | 10.3%
Free Cash Flow
17.5%
More
EPS
$2.0
FCF per Share
$2.0
Short interest
12.1%
Employees
163
Rev per Employee
$1.1m
Show more

Is Rigel Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,998 stocks worldwide.

Rigel Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

7x Buy
58%
5x Hold
42%

Analyst Opinions

12 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

Buy
58%
Hold
42%

Financial data from Rigel Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
203 203
69% 69%
100%
- Direct Costs 21 21
157% 157%
10%
182 182
62% 62%
90%
- Selling and Administrative Expenses 112 112
6% 6%
55%
- Research and Development Expense 26 26
26% 26%
13%
46 46
444% 444%
23%
- Depreciation and Amortization 2.43 2.43
90% 90%
1%
EBIT (Operating Income) EBIT 44 44
398% 398%
22%
Net Profit 37 37
288% 288%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Rigel Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rigel Pharmaceuticals, Inc. Stock News

Neutral
PRNewsWire
10 days ago
SOUTH SAN FRANCISCO, Calif. , July 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASD...
Neutral
PRNewsWire
about 2 months ago
SOUTH SAN FRANCISCO, Calif. , May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 12:50 p.m.
Neutral
PRNewsWire
about 2 months ago
Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors   Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, ...
More Rigel Pharmaceuticals, Inc. News

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Head office United States
CEO Raul Rodriguez
Employees 163
Founded 1996
Website www.rigel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today